Financial Report: Alexion 4Q13 4Q Revenues: $442 million (+38%) 4Q Loss: $19 million (earnings of $81 million in 4Q12) FY Revenues: $1.6 billion (+37%) FY Earnings: $253 million (-1%) Comments: Sales of the company’s sole commercial product, Soliris, continued to grow as it added new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion took a $153 million charge during FY13 in connection with centralizing certain business opera...